SCHEDULE 13G/A: Pacer Funds and Affiliates Disclose 1.06% Passive Stake in Collegium Pharmaceutical

Pacer US Small Cap Cash Cows ETF, Pacer US Small Cap Cash Cows Growth Leaders ETF, Pacer Advisors, Inc., and Joe M. Thomson have jointly filed an amended Schedule 13G, reporting a combined beneficial ownership of 1.06% in Collegium Pharmaceutical, Inc. as of March 31, 2025.

Summary

• Pacer US Small Cap Cash Cows ETF, Pacer US Small Cap Cash Cows Growth Leaders ETF, Pacer Advisors, Inc., and Joe M. Thomson (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• The filing reports beneficial ownership of Common Stock, Par Value $0.001 Per Share, of Collegium Pharmaceutical, Inc. (the "Issuer").
• As of March 31, 2025, the Reporting Persons collectively beneficially own 419,076 shares of Collegium Pharmaceutical, Inc. Common Stock.
• This aggregate amount represents 1.06% of the Issuer's outstanding common stock, based on 39,646,749 shares issued and outstanding as of December 31, 2024.
• Pacer US Small Cap Cash Cows ETF holds 416,333 shares, representing 1.05% of the class.
• Pacer US Small Cap Cash Cows Growth Leaders ETF holds 2,743 shares, representing 0.01% of the class.
• Pacer Advisors, Inc., as the investment adviser to the Funds, and Joe M. Thomson, as the majority stockholder of the Adviser, are deemed to have shared voting and dispositive power over the total 419,076 shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the Issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or prospects. It is neutral in tone and content.

Positives

• The filing indicates a passive investment by institutional funds, suggesting a belief in the long-term value of Collegium Pharmaceutical without intent to influence control.

Negatives

• The document does not contain information that would be considered negative regarding Collegium Pharmaceutical's operations or financial performance, as it is solely a beneficial ownership disclosure.

Risks

• The document itself does not detail specific risks related to Collegium Pharmaceutical, Inc.'s business operations or financial health. It is a disclosure of beneficial ownership.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Collegium Pharmaceutical, Inc.'s future performance or outlook. It is a disclosure of current beneficial ownership.

Industry Context

This filing is a standard disclosure required when an investor's beneficial ownership of a company's stock crosses certain thresholds. For investment funds like Pacer's ETFs, such filings indicate a passive investment strategy, where the shares are held in the ordinary course of business without an intent to influence or change control of the issuer. This is common practice for ETFs that track specific market segments, such as small-cap companies with strong cash flow characteristics, as implied by the fund names.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive institutional ownership, which can be viewed positively as it indicates institutional interest in the company's stock.
• Management: Awareness of institutional holders and their passive investment intent.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Collegium Pharmaceutical, Pacer US Small Cap Cash Cows ETF, Pacer US Small Cap Cash Cows Growth Leaders ETF, Pacer Advisors Inc., Investment Fund, Passive Investment, SEC Filing, Common Stock